Investigational drug · Phase 3
RLD2401
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Low-back Pain.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "RLD2401"
First trial start
2024
Nov 22, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RLD2401", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Low-back Pain
Approved drugs for the same conditions: Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "RLD2401" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain PatientsPivotal-lookingCompleted
Hanmi Pharmaceutical Company LimitedIndustry
NCT06595004 · 310 participants · Start Nov 22, 2024 · Primary completion Jun 18, 2025
Drug: HCP1004; RLD2401 · For: Chronic Low-back Pain
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Low-back Pain
- HCP1004Phase 31 trial
Hanmi Pharmaceutical Company Limited · Chronic Low-back Pain
- CELZ-201-DDTPhase 21 trial
Creative Medical Technology Holdings Inc · Chronic Low-back Pain, Degenerative Disc Disease
- PP353Phase 21 trial
Persica Pharmaceuticals Ltd · Chronic Low-back Pain
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.